Fenebrutinib cuts relapses and chronic lesion growth in multiple sclerosis
Roche’s fenebrutinib lowered relapses and chronic lesion growth in multiple sclerosis across late-stage trials, with FDA priority review under way.
This section contains the website’s posts.